

Florence Namour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6354607/publications.pdf>

Version: 2024-02-01

12
papers

370
citations

1040056

9
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

539
citing authors

#	ARTICLE	IF	CITATIONS
1	Filgotinib: A Clinical Pharmacology Review. <i>Clinical Pharmacokinetics</i> , 2022, 61, 819-832.	3.5	13
2	Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 901-908.	4.7	2
3	Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 32-40.	1.6	7
4	The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 585-594.	1.6	16
5	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2779-2789.	2.4	23
6	Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 1949-1959.	5.6	66
7	Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 139-148.	2.4	46
8	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. <i>Drug Metabolism Letters</i> , 2016, 10, 38-48.	0.8	49
9	Author's Reply to Srinivas: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1297-1298.	3.5	7
10	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. <i>Clinical Pharmacokinetics</i> , 2015, 54, 859-874.	3.5	112
11	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 741-744.	0.9	18
12	Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects. <i>Drugs in R and D</i> , 2012, 12, 141-163.	2.2	11